MEMBER PREVIEW
The latest company update sets a five-year biosimilars revenue ambition, lifts planned manufacturing investment and separates higher-risk oncology funding.
FREE MEMBER LOGIN
LOGIN TO CONTINUE READING.
Create or use your free IMG login to read standard articles. Important and Premium analysis also requires an active ₹99 or ₹199 plan.
The public preview and the member article share the same canonical page. No personalised investment recommendation is provided.